DanCann Pharma A/S: Quarterly CEO Reflection
COPENHAGEN, Denmark, 14 August 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces the CEO’s reflections following the publication of the Company’s Q2-2024 report.CEO, Jeppe Krog Rasmussen, comments: Financials: Record revenue and positive EBITDA DanCann Pharma closed Q2-2024 with a record revenue of DKK 3.86 million. For H1-2024, this resulted in a further record revenue of approximately DKK 4.55 million. Comparing this to the revenue of DKK 2.90 million for H1-2023, we have amassed an increase of